X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5089) 5089
Book Review (697) 697
Publication (391) 391
Book Chapter (5) 5
Conference Proceeding (5) 5
Dissertation (4) 4
Magazine Article (4) 4
Book / eBook (3) 3
Government Document (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4640) 4640
humans (4268) 4268
male (2886) 2886
female (2572) 2572
pyrroles - therapeutic use (2275) 2275
middle aged (2173) 2173
pyrroles - adverse effects (1927) 1927
atorvastatin calcium (1706) 1706
aged (1698) 1698
adult (1389) 1389
pyrroles - administration & dosage (1331) 1331
treatment outcome (1109) 1109
animals (1100) 1100
oncology (1018) 1018
heptanoic acids - therapeutic use (992) 992
pyrroles - pharmacology (976) 976
indoles - adverse effects (941) 941
indoles - therapeutic use (884) 884
sunitinib (819) 819
pharmacology & pharmacy (800) 800
atorvastatin (757) 757
carcinoma, renal cell - drug therapy (717) 717
cancer (698) 698
kidney neoplasms - drug therapy (676) 676
abridged index medicus (660) 660
statins (658) 658
heptanoic acids - adverse effects (648) 648
heptanoic acids - administration & dosage (624) 624
antineoplastic agents - therapeutic use (619) 619
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (605) 605
antineoplastic agents - adverse effects (589) 589
care and treatment (548) 548
drug therapy (523) 523
aged, 80 and over (511) 511
indoles - administration & dosage (506) 506
cardiac & cardiovascular systems (503) 503
cholesterol (500) 500
dose-response relationship, drug (495) 495
analysis (476) 476
therapy (465) 465
double-blind method (442) 442
risk factors (431) 431
pyrimidines - therapeutic use (415) 415
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (408) 408
kidney neoplasms - pathology (396) 396
anticholesteremic agents - therapeutic use (394) 394
mice (388) 388
efficacy (381) 381
cholesterol, ldl - blood (380) 380
research (379) 379
rats (377) 377
heptanoic acids - pharmacology (374) 374
simvastatin (370) 370
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (368) 368
medicine & public health (361) 361
tyrosine kinase inhibitor (358) 358
time factors (357) 357
drug therapy, combination (347) 347
niacinamide - analogs & derivatives (337) 337
retrospective studies (329) 329
safety (326) 326
medicine, general & internal (321) 321
prospective studies (319) 319
endothelial growth-factor (315) 315
pyrroles - pharmacokinetics (312) 312
metastasis (305) 305
antineoplastic agents (304) 304
drug administration schedule (302) 302
interferon-alpha (295) 295
antimitotic agents (291) 291
disease-free survival (290) 290
protein kinase inhibitors - therapeutic use (290) 290
hypercholesterolemia - drug therapy (289) 289
clinical trials (287) 287
pyrimidines - adverse effects (287) 287
sorafenib (282) 282
anticholesteremic agents - adverse effects (279) 279
protein kinase inhibitors - adverse effects (276) 276
expression (271) 271
renal-cell carcinoma (271) 271
follow-up studies (258) 258
urology & nephrology (256) 256
carcinoma, renal cell - pathology (255) 255
bevacizumab (251) 251
prevention (250) 250
trial (250) 250
antineoplastic agents - administration & dosage (247) 247
young adult (246) 246
carcinoma, renal cell (244) 244
angiogenesis inhibitors - adverse effects (240) 240
survival (239) 239
angiogenesis inhibitors - therapeutic use (237) 237
disease (235) 235
inflammation (235) 235
internal medicine (235) 235
indoles - pharmacology (234) 234
pravastatin (232) 232
clinical trials as topic (230) 230
health aspects (228) 228
pyrroles - chemistry (228) 228
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4891) 4891
French (46) 46
German (38) 38
Chinese (25) 25
Japanese (25) 25
Spanish (22) 22
Russian (16) 16
Italian (12) 12
Dutch (6) 6
Hungarian (5) 5
Swedish (3) 3
Czech (2) 2
Danish (2) 2
Polish (2) 2
Portuguese (2) 2
Croatian (1) 1
Korean (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Dermatology, ISSN 0007-0963, 11/2009, Volume 161, Issue 5, pp. 1045 - 1051
Summary Background  The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and... 
sunitinib | sorafenib | cutaneous adverse effects | Cutaneous adverse effects | Sunitinib | Sorafenib | THERAPY | HAIR | MANAGEMENT | KIT | IMATINIB | HAND-FOOT | FOOT SKIN REACTION | DERMATOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hand Dermatoses - chemically induced | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Skin Diseases - pathology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Drug Eruptions - etiology | Skin Diseases - chemically induced | Pyridines - administration & dosage | Administration, Oral | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Stomatitis - chemically induced | Foot Dermatoses - chemically induced | Alopecia - chemically induced | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article
Journal of Family Practice, ISSN 0094-3509, 09/2014, Volume 63, Issue 9, pp. 497 - 506
CASE Carl L, a 57-year-old obese patient (body mass index [BMI] >40) who had not been to a doctor in a decade, comes to see you after a health fair screening... 
MEDICINE, GENERAL & INTERNAL | THERAPY | METAANALYSIS | STROKE PREVENTION | CHOLESTEROL | CARDIOVASCULAR EVENTS | SAFETY | INTRACEREBRAL HEMORRHAGE | PRIMARY HEALTH CARE | MYOPATHY | INCIDENT CATARACT | AGGRESSIVE REDUCTION | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Drug-Related Side Effects and Adverse Reactions - prevention & control | Hyperlipidemias - blood | Clinical Trials as Topic - statistics & numerical data | Evidence-Based Practice | Outcome Assessment (Health Care) | Risk Adjustment | Humans | Rhabdomyolysis - therapy | Drug Monitoring - methods | Heptanoic Acids - adverse effects | Rhabdomyolysis - diagnosis | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Pyrroles - adverse effects | Ubiquinone - administration & dosage | Hyperlipidemias - drug therapy | Ubiquinone - analogs & derivatives | Drug-Related Side Effects and Adverse Reactions - etiology | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Rhabdomyolysis - chemically induced | Drug Monitoring - statistics & numerical data | Drug-Related Side Effects and Adverse Reactions - physiopathology | Drug-Related Side Effects and Adverse Reactions - classification | Drug-Related Side Effects and Adverse Reactions - diagnosis | Vitamins - administration & dosage | Practice Guidelines as Topic | Drugs | Case studies | Complications and side effects | Usage | Adverse and side effects | Research | Statins | Index Medicus | Abridged Index Medicus
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2015, Volume 115, Issue 4, pp. 447 - 453
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
Scandinavian Journal of Medicine & Science in Sports, ISSN 0905-7188, 10/2013, Volume 23, Issue 5, pp. 556 - 567
The aim of the present study was to investigate the effects of a repeated bout of eccentric exercise on health‐related parameters and muscle performance on... 
eccentric exercise | substrate oxidation | insulin resistance | muscle damage | hypercholesterolemia | lipid profile | Lipid profile | Insulin resistance | Hypercholesterolemia | Eccentric exercise | Substrate oxidation | Muscle damage | SPORT SCIENCES | COA REDUCTASE INHIBITORS | STRENGTH | MYOPATHY | HUMAN SKELETAL-MUSCLE | ANTIOXIDANT SUPPLEMENTATION | DAMAGE | THERAPY | RESISTANCE | CREATINE-KINASE | Body Constitution | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - therapeutic use | Humans | Diet Records | Maximal Voluntary Ventilation - physiology | Male | Heptanoic Acids - adverse effects | Hypercholesterolemia - drug therapy | Case-Control Studies | Exercise Test | Pyrroles - administration & dosage | Muscle, Skeletal - drug effects | Heptanoic Acids - administration & dosage | Pyrroles - adverse effects | Adipose Tissue | Pyrroles - therapeutic use | Body Mass Index | Muscle, Skeletal - physiology | Maximal Voluntary Ventilation - drug effects | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged | Exercise - physiology | Energy Metabolism - drug effects | Complications and side effects | Exercise | Analysis | Physiological aspects | Exercise for the aged | Statins | Restaurants | Muscular system | Older people | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis.... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | ATHEROSCLEROSIS | INTRAVASCULAR ULTRASOUND | RANDOMIZED CONTROLLED-TRIAL | AVERAGE CHOLESTEROL LEVELS | ROSUVASTATIN | ARTERY-DISEASE | ATORVASTATIN | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Ultrasonography | Atorvastatin | Heart diseases | Lipoproteins (high density) | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Index Medicus | Abridged Index Medicus | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
Objective To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).Design Population based cohort... 
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | THERAPY | EVENTS | CHOLESTEROL | CORONARY | DISEASE | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Cardiovascular Diseases - epidemiology | Heptanoic Acids - administration & dosage | Pravastatin - adverse effects | Pyrroles - adverse effects | Diabetes Mellitus, Type 2 - etiology | Female | Retrospective Studies | Odds Ratio | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Atorvastatin Calcium | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pravastatin - administration & dosage | Ontario - epidemiology | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Diabetes Mellitus, Type 2 - chemically induced | Population Surveillance | Sulfonamides - administration & dosage | Cohort Studies | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2014, Volume 370, Issue 25, pp. 2377 - 2386
In patients with rheumatoid arthritis, tofacitinib was associated with greater reductions in signs and symptoms than methotrexate. Herpes zoster infections and... 
MEDICINE, GENERAL & INTERNAL | MODIFYING ANTIRHEUMATIC DRUGS | RECOMMENDATIONS | COMBINATION THERAPY | JOINT DAMAGE | DISEASE | PLUS METHOTREXATE | DOUBLE-BLIND | RANDOMIZED-TRIAL | ETANERCEPT | CLINICAL-OUTCOMES | Herpes Zoster - etiology | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | Cholesterol - blood | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Arthritis, Rheumatoid - complications | Dose-Response Relationship, Drug | Janus Kinase 3 - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Methotrexate - adverse effects | Protein Kinase Inhibitors - administration & dosage | Piperidines - adverse effects | Pyrimidines - adverse effects | Creatinine - blood | Methotrexate - administration & dosage | Care and treatment | Dosage and administration | Tofacitinib | Comparative analysis | Methotrexate | Rheumatoid arthritis | Creatinine | Herpes zoster | C-reactive protein | Kinases | Joint diseases | E.S.R | Lymphoma | Sedimentation | Cholesterol | Pain | Rheumatism | Janus kinase | Drug therapy | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus
Journal Article